p16 and its putative interplay with metabolic factors in prostate cancer: An analysis based on public TCGA data

Boldrini,Laura; Manassero,Francesca; Selli,Cesare; Bartoletti,Riccardo; Faviana,Pinuccia

doi:10.3892/wasj.2020.33

p16 and its putative interplay with metabolic factors in prostate cancer: An analysis based on public TCGA data

Authors:
- Laura Boldrini
- Francesca Manassero
- Cesare Selli
- Riccardo Bartoletti
- Pinuccia Faviana
View Affiliations

Affiliations: Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, I‑56126 Pisa, Italy, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, I‑56126 Pisa, Italy
Published online on: January 21, 2020 https://doi.org/10.3892/wasj.2020.33
Pages: 9-13
Copyright: © Boldrini et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

p16 is one of the most common tumour suppressor genes, mainly due to its genetic inactivation. However, the clinical significance of p16 in prostate cancer is not yet fully understood, and although p16 acts as a tumour suppressor gene, stress or oncogenic factors or alternative molecular events may overcome the role of p16 as a negative cell cycle regulator. p16 seems to be involved in the metabolic switch to glycolysis during tumorigenesis, possibly interacting with NADPH oxidase 4 (NOX4) and pyruvate kinase type M2 (PKM2), involved in energy metabolism, with differences depending on cell type. The aim of this study was to assess the putative crosstalk between p16, NOX4 and PKM2, with an involvement of miRNA‑mediated regulation, in prostate cancer. Transcriptome data from a cohort of 243 patients were extracted from The Cancer Genome Atlas (TCGA) database. An elevated p16 expression level was significantly associated a high Gleason score, decreasing with the score (P<0.0001). NOX4 and PKM2 expression exhibited a similar trend as p16, with higher values in the samples with Gleason scores of 9‑10 samples (P<0.0001 and P=0.02, respectively). Moreover, bioinformatics analysis by TargetScan revealed that miR‑625‑5p could bind to the 3'UTR of p16. A consequential pairing of the NOX4 and PKM2 target region with miR‑23a‑3p and miR‑122‑5p, respectively was also found. Of note, the miR‑625‑5p levels inversely correlated with p16 expression, miR‑23a‑3p and miR‑122 with NOX4 and PKM2, respectively (data not shown). Taken together, these data suggest an interplay between p16 and metabolic factors, such as NOX4 and PKM2, and a miRNA regulation, with a potential clinical impact for the development of novel therapeutic strategies in prostate tumours.

View Figures

View References

1	Serrano M, Hannon GJ and Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclinD-cdk4. Nature. 366:704–707. 1993.PubMed/NCBI View Article : Google Scholar
2	Serrano M: The tumor suppressor protein p16INK4a. Exp Cell Res. 237:7–13. 1997.PubMed/NCBI View Article : Google Scholar
3	Liggett WH and Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol. 16:1197–1206. 1998.PubMed/NCBI View Article : Google Scholar
4	Tamimi Y, Bringuier PP, Smit F, van Bokhoven A, Debruyne FM and Schalken JA: p16 mutations/deletions are not frequent events in prostate cancer. Brit J Cancer. 74:120–122. 1996.PubMed/NCBI View Article : Google Scholar
5	Taga S, Osaki T, Ohgami A, Imoto H, Yoshimatsu T, Yoshino I, Yano K, Nakanishi R, Ichiyoshi Y and Yasumoto K: Prognostic value of the immunohistochemical detection of p16INK4 expression in non small cell lung carcinoma. Cancer. 80:389–395. 1997.PubMed/NCBI View Article : Google Scholar
6	García-Sanz R, González M, Vargas M, Chillón MC, Balanzategui A, Barbón M, Flores MT and San Miguel JF: Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia. 11:1915–1920. 1997.PubMed/NCBI View Article : Google Scholar
7	Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 40:120–126. 2016.PubMed/NCBI View Article : Google Scholar
8	Mahajan A: Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. Hum Pathol. 51:64–74. 2016.PubMed/NCBI View Article : Google Scholar
9	Serra S and Chetty R: p16. J Clin Pathol. 71:853–858. 2018.PubMed/NCBI View Article : Google Scholar
10	Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res. 5:977–983. 1999.PubMed/NCBI
11	Burdelski C, Dieckmann T, Heumann A, Hube-Magg C, Kluth M, Beyer B, Steuber T, Pompe R, Graefen M, Simon R, et al: p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumour Biol. 37:12655–12663. 2016.PubMed/NCBI View Article : Google Scholar
12	Li J, Poi MJ and Tsai MD: Regulatory mechanisms of tumor suppressor P16(INK4A) and their relevance to cancer. Biochemistry. 50:5566–5582. 2011.PubMed/NCBI View Article : Google Scholar
13	Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, et al: Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun. 8(14437)2017.PubMed/NCBI View Article : Google Scholar
14	Zhu H, Luo H and Zhu X, Hu X, Zheng L and Zhu X: Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: A meta-analysis. Oncotarget. 8:1628–1640. 2017.PubMed/NCBI View Article : Google Scholar
15	Goldberg MS and Sharp PA: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 209:217–224. 2012.PubMed/NCBI View Article : Google Scholar
16	Hsu MC, Hung WC, Yamaguchi H, Lim SO, Liao HW, Tsai CH and Hung MC: Extracellular PKM2 induces cancer proliferation by activating the EGFR signalling pathway. Am J Cancer Res. 6:628–638. 2016.PubMed/NCBI View Article : Google Scholar
17	Singh H, Longo DL and Chabner BA: Improving prospects for targeting RAS. J Clin Oncol. 33:3650–3659. 2015.PubMed/NCBI View Article : Google Scholar
18	Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 108:4129–4134. 2011.PubMed/NCBI View Article : Google Scholar
19	Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 480:118–122. 2011.PubMed/NCBI View Article : Google Scholar
20	Wong N, Yan J, Ojo D, De Melo J, Cutz JC and Tang D: Changes in PKM2 associate with prostate cancer progression. Cancer Invest. 32:330–338. 2014.PubMed/NCBI View Article : Google Scholar
21	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009.PubMed/NCBI View Article : Google Scholar
22	Straume O and Akslen L: Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer. 74:535–539. 1997.PubMed/NCBI View Article : Google Scholar
23	Wu QQ, Zheng B, Weng GB, Yang HM, Ren Y, Weng XJ, Zhang SW and Zhu WZ: Downregulated NOX4 underlies a novel inhibitory role of microRNA-137 in prostate cancer. J Cell Biochem. 120:10215–10227. 2019.PubMed/NCBI View Article : Google Scholar
24	Yoshida GJ: Metabolic reprogramming: The emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 34(111)2015.PubMed/NCBI View Article : Google Scholar
25	Dey P, Kundu A, Sachan R, Park JH, Ahn MY, Yoon K, Lee J, Kim ND, Kim IS, Lee BM and Kim HS: PKM2 knockdown induces autophagic cell death via AKT/mTOR pathway in human prostate cancer cells. Cell Physiol Biochem. 52:1535–1552. 2019.PubMed/NCBI View Article : Google Scholar
26	Etheridge A, Lee I, Hood L, Galas D and Wang K: Extracellular microRNA: A new source of biomarkers. Mutat Res. 717:85–90. 2011.PubMed/NCBI View Article : Google Scholar
27	Volinia S and Croce CM: Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci USA. 110:7413–7417. 2013.PubMed/NCBI View Article : Google Scholar
28	Feber A, Xi L, Pennathur A, Gooding WE, Bandia S, Wu M, Luketich JD, Godfrey TE and Litle VR: MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 91:1523–1530. 2011.PubMed/NCBI View Article : Google Scholar
29	Beer DG, Kardia SL, Huang C, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 8:816–824. 2002.PubMed/NCBI View Article : Google Scholar
30	Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H and Chinnaiyan AM: Development of a RNA-Seq based prognostic signature in lung adenocarcinoma. J Natl Cancer Inst. 109:2016.PubMed/NCBI View Article : Google Scholar